Pivotal Evaluation of the Access Natriuretic Peptdie Assay(s) as an Aid in the Diagnosis and Assessment of Severity of Acute Heart Failure - Emergency Department Subject Enrollment and Specimen Collection
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Beckman Coulter, Inc.
- Enrollment
- 2,370
- Locations
- 15
- Primary Endpoint
- Sensitivity and Specificity of the future Natriuretic Peptide Assay(s)
Study Overview
Brief Summary
The purpose of the pivotal study is to collect blood specimens and clinical data from patients suspected of having Heart Failure (HF), which will be tested at a future date on Natriuretic Peptide assay(s) to validate diagnostic cutoffs and assess HF severity.
Detailed Description
A prospective clinical sample collection and future natriuretic peptide testing will be conducted in an emergency department only population. Patients presenting to the Emergency Department (ED) with signs and symptoms of acute heart failure will be approached for enrollment.
Clinical and laboratory data will be collected to establish product performance and clinical concordance to adjudicated clinical diagnosis. Approximately 1800 evaluable subjects at geographically dispersed sites in the US will be enrolled in the study.
Sample collection and testing of clinical samples with the Access Natriuretic Peptide assay will be performed under two separate protocols
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 21 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed and dated informed consent obtained
- •Adult aged 21 years or older
- •Presenting with a clinical suspicion of acute HF
- •Subject clinical history available for review by Sponsor or delegates and FDA or other regulatory agencies
Exclusion Criteria
- •Dyspnea clearly not secondary to HF (e.g. primary lung disease or chest trauma)
- •Stage 4 or 5 Chronic Kidney Disease (CKD)
- •Chronic dialysis
- •Participation in a clinical study that may interfere with participation in this study
- •Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
Outcomes
Primary Outcomes
Sensitivity and Specificity of the future Natriuretic Peptide Assay(s)
Time Frame: Single blood draw upon study entry at day 1
Establish the performance of the future Natriuretic Peptide assay(s) against the adjudicated diagnosis.
Secondary Outcomes
- Heart Failure Severity Assessment(Single blood draw upon study entry at day 1 and two remote follow up visits)